Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 100Carcinoma, Non-Small-Cell Lung 48Neoplasms 34Urinary Bladder Neoplasms 25Lung Neoplasms 25Cholangiocarcinoma 23Breast Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 13Lymphoma 13Recurrence 12Lymphoma, Large B-Cell, Diffuse 11Biliary Tract Neoplasms 11Sarcoma 10Carcinoma, Transitional Cell 9Hodgkin Disease 8Gallbladder Neoplasms 8Fallopian Tube Neoplasms 8Adenocarcinoma 8Bile Duct Neoplasms 7Colorectal Neoplasms 6Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Liver Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4

Interventions

pemigatinib 2pembrolizumab 1derazantinib 1brivanib 1Rogaratinib 1Irinotecan 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Acrocephalosyndactylia × Gemcitabine × Clear all
NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡